Arcutis Biotherapeutics, Inc. (ARQT)
25.55
-1.45
(-5.37%)
USD |
NASDAQ |
Nov 06, 16:00
25.56
+0.01
(+0.04%)
After-Hours: 20:00
Arcutis Biotherapeutics Cash from Investing (Quarterly) : -22.08M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -22.08M |
| June 30, 2026 | -15.22M |
| March 31, 2026 | -11.33M |
| December 31, 2025 | -34.18M |
| September 30, 2025 | -25.25M |
| June 30, 2025 | 17.42M |
| March 31, 2025 | 11.75M |
| December 31, 2024 | 34.88M |
| September 30, 2024 | 84.78M |
| June 30, 2024 | -62.14M |
| March 31, 2024 | -28.70M |
| December 31, 2023 | -62.19M |
| September 30, 2023 | 45.55M |
| June 30, 2023 | 89.12M |
| March 31, 2023 | 107.75M |
| December 31, 2022 | 42.20M |
| Date | Value |
|---|---|
| September 30, 2022 | -197.26M |
| June 30, 2022 | 52.56M |
| March 31, 2022 | 15.30M |
| December 31, 2021 | 23.50M |
| September 30, 2021 | 3.471M |
| June 30, 2021 | -164.92M |
| March 31, 2021 | 62.00M |
| December 31, 2020 | -75.89M |
| September 30, 2020 | -91.71M |
| June 30, 2020 | 6.105M |
| March 31, 2020 | -20.33M |
| December 31, 2019 | -36.00M |
| September 30, 2019 | 21.18M |
| June 30, 2019 | -2.241M |
| March 31, 2019 | -9.27M |
| December 31, 2018 | -11.53M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -- |
| ADMA Biologics, Inc. | -2.068M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 18.90M |
| Cash from Financing (Quarterly) | 2.453M |
| Free Cash Flow | 59.71M |
| Free Cash Flow Per Share (Quarterly) | 0.1374 |
| Free Cash Flow to Equity (Quarterly) | 9.118M |
| Free Cash Flow to Firm (Quarterly) | 21.70M |
| Free Cash Flow Yield | 1.74% |